According to a press release issued by the Schlieren-based biotechnology firm Molecular Partners, the COVID-19 drug ensovibep has proven to be effective and well tolerated in a Phase 2 study involving 407 patients carried out in conjunction with Novartis. Moreover, ensovibep is effective against all known variants, including Omicron. Following this positive data, Novartis has announced its intention to exercise its option to acquire licensing rights for ensovibep. As such, Novartis will make a milestone payment of 150 million Swiss francs, while Molecular Partners will also be entitled to a 22 percent royalty on sales in connection with commercialization activities for the drug.
Novartis will now turn its attention to accelerating scale-up plans for manufacturing activities and rapidly securing global regulatory authorizations. In a first step, the company will apply for an EUA (Emergency Use Authorization) from the US Food and Drug Administration (FDA).
The study confirmed that treatment with ensovibep led to a reduction in viral load within eight days as well as a 78 percent decline in emergency room admissions, hospital stays and deaths.
“Today’s data are a culmination of a persistent team effort, between ourselves and Novartis, to deliver a tailored antiviral with demonstrated safety and efficacy in global clinical trials”, comments Patrick Amstutz, CEO of Molecular Partners, in the press release. “As COVID-19 continues to burden healthcare systems across the globe, a range of treatments will be needed”, comments Novartis CEO Vas Narasimhan. For this reason, Novartis will continue its collaboration with Molecular Partners.
Biotech in Greater Zurich
The Greater Zurich Area is one of the leading locations for biotechnology and pharmaceutical companies in Europe. The region is home to the innovative companies in the world, from Biogen and Johnson & Johnson to Roche and Amgen, and attracts capital and researchers from all over the world.